HIF1A and cancer: In contrast, as reported in the literature for the capability of A3AR agonists to enhance HIF‐1α mRNA and protein expression in different cancers, our results show a reduction in HIF‐1α protein levels in A3AR antagonist‐treated PCa cells, likely supporting an A3AR‐dependent effect.